CNIO researchers explain the toxicity of USP7 inhibitors, under development for cancer treatment

(Centro Nacional de Investigaciones Oncol ó gicas (CNIO)) The researchers have discovered that USP7 inhibitors -under development by several pharmaceutical companies for the treatment of cancer- trigger a premature activation of cell cycle proteins, leading to uncontrolled cancer cell division and death.* The paper rejects the premise that the therapeutic efficacy of these inhibitors is due to their effects on activating the tumor suppressor protein P53, as currently accepted by the international scientific community. These results extend the potential use of USP7 inhibitors to a wider range of patients.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news